Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
February 03 2016 - 6:05AM
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
today announced the addition of two members to the senior
management team. Martha Manning, Esq., joins Achillion as Executive
Vice President, General Counsel and Secretary effective February 1,
2016. In addition, Amy Jennings, Ph.D., recently joined the Company
and will serve as Senior Vice President of Regulatory Affairs.
“The high caliber of individuals, including both
Martha and Amy, who have joined Achillion in recent months
highlights the excitement for Achillion’s factor D inhibitor
program and the potential for our small molecule compounds to
address the unmet needs of patients with ultra-rare diseases,”
commented Milind Deshpande, Ph.D., President and Chief Executive
Officer. “I am pleased to welcome Martha, who joins us with more
than two decades of industry experience at pharmaceutical companies
both large and small, and Amy, who most recently was the head of
U.S. regulatory for diabetes at Sanofi. I believe that their
addition to the Achillion team further enhances our goal of
maturing into a commercial pharmaceutical company.”
Martha E. Manning, Esq.
Martha E. Manning, Esq. joined Achillion in
February 2016 as General Counsel. Previously, she was General
Counsel of iCeutica Inc., a drug development company from 2013 to
2016. She served as Chief Legal Officer of OraPharma, Inc., a
J&J spinout company, from 2011 to 2012 when the Company was
acquired by Valeant. She joined OraPharma from Sandoz Inc., the
generic pharmaceutical division of Novartis, where she served as
Vice President and General Counsel from 2008 to 2011. Prior to
Sandoz, she served as Senior Vice President, General Counsel and
Secretary for Adolor Corporation, a publicly traded
biopharmaceutical company from 2002 to 2008. Martha began her legal
career with the law firm of Morgan, Lewis & Bockius. She
received her J.D. from the University of Pennsylvania School of Law
and her Bachelor of Business Administration from the University of
Massachusetts.
Amy Jennings, Ph.D.
Amy Jennings joined Achillion in January 2016
and serves as Senior Vice President of Regulatory Affairs. She was
previously with Sanofi where she was the head of US regulatory for
diabetes. Prior to Sanofi, Amy assumed roles of increasing
responsibility at Bristol-Myers Squibb within Regulatory over more
than 12 years, culminating in her leading U.S. regulatory for
CV/Metabolics. During her tenure at BMS, she was involved with both
U.S. and Global regulatory for all phases of drug development,
across broad therapeutic areas, and contributed to multiple drug
approvals, including leading the U.S. regulatory efforts for the
recent approvals of Farxiga and Xigduo XR for patients with type 2
diabetes. To obtain the U.S. approval of Farxiga, Amy led the team
through the NDA submission, preparation of two advisory committee
meetings, and an NDA resubmission.
Amy earned a BS in Chemistry from the University
of Wisconsin-Madison and a Ph.D. in Biochemistry from The Ohio
State University. She was a post-doctoral fellow at the Joslin
Diabetes Center prior to joining the pharmaceutical industry.
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is
a science-driven, patient-focused company seeking to leverage its
strengths across the continuum from discovery to commercialization
in its goal of providing better treatments for people with serious
diseases. The company employs a highly-disciplined discovery and
development approach that has allowed it to pursue best-in-class
oral antiviral therapy for chronic hepatitis C (HCV) and build a
platform of potent and specific complement inhibitors. Achillion is
rapidly advancing its efforts to become a fully-integrated
pharmaceutical company with a goal of bringing life-saving
medicines to patients with rare diseases. More information is
available at http://www.achillion.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements.
Achillion may use words such as “expect,” “anticipate,” “project,”
“intend,” “plan,” “aim,” “believe,” “seek,” “ estimate,” “can,”
“focus,” “will,” “look forward,” “goal,” and “may” and similar
expressions to identify such forward-looking statements. These
forward-looking statements also include statements about the:
potential for the Company’s complement inhibitor compounds to
address the unmet needs of patients with ultra-rare diseases; and
the Company’s strategic goals. Among the important factors that
could cause actual results to differ materially from those
indicated by such forward-looking statements are risks relating to,
among other things Achillion’s ability to: advance the preclinical
and clinical development of its drug candidates, including its
complement factor D inhibitors, under the timelines it projects in
current and future preclinical studies and clinical trials; obtain
and maintain patent protection for its drug candidates and the
freedom to operate under third party intellectual property;
demonstrate in any current and future clinical trials the requisite
safety, efficacy and combinability of its drug candidates; obtain
and maintain necessary regulatory approvals; establish commercial
manufacturing arrangements; identify, enter into and maintain
collaboration agreements with third-parties; compete successfully
in the markets in which it seeks to develop and commercialize its
product candidates and future products; manage expenses; manage
litigation; raise the substantial additional capital needed to
achieve its business objectives; and successfully execute on its
business strategies. These and other risks are described in the
reports filed by Achillion with the U.S. Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2015, and its subsequent SEC
filings.
In addition, any forward-looking statement in
this press release represents Achillion’s views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Company Contact: |
Media: |
Glenn Schulman |
Liz Power |
Achillion Pharmaceuticals, Inc. |
Achillion Pharmaceuticals, Inc. |
Tel. (203) 624-7000 |
Tel: (203) 752-5509 |
gschulman@achillion.com |
lpower@achillion.com |
|
|
Investors: |
Investors: |
Mary Kay Fenton |
Tricia Truehart |
Achillion Pharmaceuticals, Inc.
|
The Trout Group, LLC |
Tel. (203) 624-7000 |
Tel. (646) 378-2953 |
mfenton@achillion.com |
ttruehart@troutgroup.com |
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024